Synbiotics
OtherOral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
NCT Number: NCT05966649
Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated.
Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth.
Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation).
Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Universitaire Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
Matching placebo
Time frame: Through study completion - at delivery
Time frame: Through study completion - at delivery
Time frame: Through study completion - at delivery
Time frame: Up to 34 weeks from the date of randomization
Incidence
Time frame: Up to 34 weeks from the date of randomization
Gestational age at PPROM
Time frame: Up to 34 weeks from the date of randomization
Time to delivery
Time frame: Assessed 3 times during the study period: at randomization, 11-13 weeks after randomization (at gestational age 19-21 weeks), and 21-23 weeks after randomization (29-31 weeks of gestation)
The vaginal microbiome will be assessed throughout pregnancy at 4 well-defined stages of pregnancy (9, 20, 30 weeks and at delivery) and at admission at the MIC unit for preterm labor, PPROM or cervical insufficiency.
Time frame: Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Time frame: Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Time frame: Up to 34 weeks from the date of randomization
Time frame: Up to 34 weeks from the date of randomization
Time frame: Trough study completion, on average 1 year
Using EQ5D questionnaire (5 questions and scale from 1 to 100)
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Sepsis (early, late and culture negative), number of episodes (min 72 hours) of antibiotic treatment, duration of antibiotic treatment in days
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Proportion of each category (no, mild, moderate and severe)
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Incidence
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Incidence
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Need for respiratory support (CPAP: continuous positive airways pressure, non-invasive positive pressure ventilation or mechanical endotracheal ventilation) and the duration of respiratory support in days. Use and administration of surfactant
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Incidence
Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)
Incidence
Time frame: After the neonate is born
Time frame: During pregnancy until 28 days after PPROM
When the patient is admitted in case the pregnancy was complicated with PPROM
Time frame: Between 13 to 36 weeks from the date of randomization
When the neonate is born after a pregnancy complicated with PPROM
Time frame: Between 13 to 36 weeks from the date of randomization
In case the pregnancy was complicated with preterm birth (delivery before 37 weeks of gestation)
Contact information is provided by the study sponsor or research team.
Caroline Van Holsbeke, PhD
CONTACT
Katrien Nulens, MD
CONTACT
Ziekenhuis Oost-Limburg
Other
Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIal
Acronym: PRIORI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05430321
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Gaziantep, Turkey (Türkiye)
View Trial DetailsNCT05385939
Communicable Diseases, Disease Attributes
Newark, Delaware, United States
View Trial DetailsNCT04325308
Behavior, Breast Feeding
Birmingham, Alabama, United States
View Trial DetailsNCT03997266
Communicable Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mobile, Alabama, United States
View Trial Details